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Abstract  
 
Background 
Respiratory failure and dysfunction are problems common in many neurodegenerative 
conditions and although physiotherapists manage these problems, it is not known which 
treatments have been studied and the efficacy of those treatments.  
Objective 
The purpose is to review, using the PRISMA approach, evidence related to the management 
of respiratory problems in people with neurodegenerative conditions in order to provide 
evidence for physiotherapy practice.  
Data sources 
Comprehensive searches were conducted using the following electronic databases from 
inception to May 2010: HUGEnet, SIGLE, British Library Direct, CINAHL, Medline, AMED, 
and Web of Knowledge. Bibliographies of all studies and systematic reviews were searched 
by hand.  
Study selection 
Studies were selected based on: self ventilating participants with neurodegenerative 
conditions; interventions aimed at improving respiratory function; outcomes were any valid 
and reliable measures of respiratory function.  
Study appraisal 
Studies were appraised by one reviewer using the Critical Appraisal Skills Programme. Data 
was synthesised using a narrative approach. 
Results 
Thirty five studies were included in the review. The strongest evidence was for the use of 
non-invasive ventilation for people with amyotrophic lateral sclerosis, although this was 
weak. The evidence for the use of respiratory muscle training and methods to increase peak 
cough flow shows a positive effect, but is also weak. 
Conclusion 
There is weak evidence for the positive effects of physiotherapy interventions for respiratory 
problems in people with neurodegenerative conditions. Further work is necessary in specific 
neurodegenerative conditions to identify why respiratory problems occur and larger scale 
studies to investigate management of these problems. 
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Introduction 
 
Rationale 
Respiratory dysfunction is common in neurodegenerative conditions for example multiple 
sclerosis (1) amyotrophic lateral sclerosis (2) and Huntington’s disease (3).  
Physiotherapy management of respiratory problems is often supportive rather than 
preventative, taking place only in the middle and late stages of the condition (4).  With the 
exception of national guidelines for the use of non-invasive ventilation in people with motor 
neurone disease (5) there are no national guidelines for the management of respiratory 
problems in people with Parkinson’s disease, Huntington’s disease or multiple sclerosis. The 
BTS/ACPRC (6) guidelines for the adult, spontaneously breathing patient focuses on people 
with neuromuscular disease but does not provide sufficient detail for neurodegenerative 
conditions. Neurodegenerative conditions differ to neuromuscular disease in that the former 
refers to central neurological disorders, whereas neuromuscular refers to post 
neuromuscular junction disorders. Multiple sclerosis, Parkinson’s disease, Huntington’s 
disease and amyotrophic lateral sclerosis/motor neurone disease (ALS/MND) are 
neurodegenerative with central nervous system processing problems and peripheral 
weakness.  
People with neurodegenerative conditions have difficulties clearing secretions for a number 
of reasons; including respiratory muscle weakness and bulbar insufficiency (7). Ineffective 
gaseous exchange may occur due to retained secretions, compounded by respiratory 
muscle weakness affecting effectiveness of cough. Decreased inspiratory muscle strength 
may lead to alveolar hypoventilation, ventilation-perfusion mismatch and further respiratory 
muscle fatigue due to altered biomechanics (8).  A gap in knowledge exists relating to the 
physiotherapy management of respiratory problems in people with neurodegenerative 
conditions, despite being the leading cause of death in this population (7) 
 
 
Objective 
The purpose of this paper is to review, using the PRISMA statement (9), evidence related to 
the management of respiratory problems in people with neurodegenerative conditions in 
order to influence physiotherapy practice.  
 
Methods 
 
Search process 
A PICO (Population, Intervention, Comparison, and Outcome) approach was used (10, 11). 
The population was defined as people with neurodegenerative conditions. The intervention 
was any physiotherapy-based intervention influencing the respiratory system. No set 
comparisons were made or follow up times set. Outcome was any reliable and valid 
measure of respiratory function and not solely respiratory failure. 
Comprehensive searches were conducted using the following electronic databases from 
inception to May 2010 (number of studies identified in brackets): HUGEnet (161), SIGLE 
(624), British Library Direct (192), CINAHL (130), Medline, EMBASE and AMED (4,307). 
Bibliographies of all studies and systematic reviews were searched by hand. Key words 
were structured using PICO. Population keywords included ‘neuro*’, ‘Parkinson’s disease’, 
‘Amyotrophic Lateral Sclerosis’, ‘Motor Neurone Disease’, ‘Multiple Sclerosis’, and 
‘Huntington’s disease’. Intervention keywords included ‘physiotherapy’ and ‘respiratory’ with 
outcome words included ‘lung’. Subsequent to the initial search and analysis of the 
categories of evidence found, two further search terms were used; respiratory muscle 
strength and retained secretions. See Figure 1 for the search strategy used in CINAHL, 
Medline, AMED and EMBASE databases.  
 
Figure 1  
 
 
Eligibility criteria, identification and selection of studies 
Full text English language randomised controlled trials, experimental studies, prospective 
and retrospective observational studies which investigated changes in respiratory function 
following a physiotherapy-based intervention were included. One reviewer identified and 
reviewed all titles and abstracts followed by full text. Exclusion criteria were: 
 Population solely neuromuscular conditions such as myesthenia gravis and muscular 
dystrophies; 
 Population entirely aged less than 18; 
 Population not spontaneously breathing; 
 Intervention did not influence respiratory function; 
 Sample n=1; 
 Outcome measure solely respiratory failure; 
 
Critical appraisal 
Critical appraisal was carried out by one reviewer using the Critical Appraisal Skills 
Programme (CASP) appraisal tool (12).  
 
Data analysis 
Analysis was completed by one reviewer. Due to heterogeneity of populations, interventions 
and outcome measures it was not possible to carry out a meta-analysis. A narrative review 
was carried out of all included studies. 
 
Results 
 
Study selection 
A total of 5,414 studies were retrieved with 5,368 being excluded by title, abstract or method, 
see Figure 2. Eleven studies were excluded by full text (available from authors on request). 
Descriptive analysis of the remaining 35 studies highlighted three main themes: the problem 
of retained secretions, the problem of decreased muscle strength and the influence of 
exercise on respiratory function.  Studies were grouped into these themes for the narrative 
review.  
 
Figure 2 
 
Critical appraisal 
A summary of the critical appraisal, following the CASP approach (12), of all selected studies 
(n=35) is in Table 1. Populations were clearly defined in all studies; only two studies carried 
out power calculations. In those studies (n=6) that required allocation to groups, this was 
defined. Random allocation was defined in the seven randomised controlled trials (RCT). 
Reproducibility of interventions was variable (14/35 not reproducible), reasons including 
retrospective studies and inadequate information given. All outcome measures were defined, 
reliable and valid but in comparable studies, different outcome measures were used. 
Generalisability of the findings was low for the majority of studies due to lack of power and 
non-reproducible interventions. 
 
Table 1 
 
Study characteristics and synthesis of results 
Based on descriptive analysis of selected studies, three main themes were identified; the 
problem of retained secretions (n=10), the problem of decreased respiratory muscle strength 
(n=19) and the influence of exercise on respiratory function (n=6). The theme of retained 
secretions was sub divided into interventions to improve cough effectiveness (n=7) and 
interventions to mobilise secretions (n=3). The theme of decreased respiratory muscle 
strength was subdivided into non-invasive ventilation (n=10) and respiratory muscle training 
(n=9). The third theme included studies related to exercise.  Details of study characteristics 
are summarised in Tables 2-5.  
The problem of retained secretions 
Ten studies (see Table 2) described intervention for retained secretions due to ineffective 
cough.  All studies were small, populations were ALS/MND (n=6) and other 
neurodegenerative conditions (n=4). Six studies compared combinations of increasing 
maximal insufflation capacity (MIC), maximum insufflation-exsufflation (MIE) and manually 
assisted cough (MAC). Three studies used high frequency chest wall oscillation (HFCWO) 
as an intervention to mobilise secretions and one study investigated mechanical glottis to 
enhance cough. The primary outcome measure for most studies (7/10) was peak cough flow 
(PCF) with two using peak expiratory flow rate (PEFR) and one using forced vital capacity 
(FVC) and oxygen saturation (SaO2).  
 
Table 2 
 
Studies relating to improvement of cough effectiveness 
Winck et al 2004 (13) investigated the effects of mechanical insufflation-exsufflation on 
parameters including PCF, SaO2, and dyspnoea. The sample was 13 subjects with ALS and 
7 subjects with other neurodegenerative conditions. PCF and SaO2 were measured at 
baseline and after MIE ±40 cmH2O and showed a significant improvement in subjects with 
ALS (p<0.005 PCF and SaO2) and other neurodegenerative conditions (PCF p<0.05, SaO2 
p<0.005). Dyspnoea was measured in the neurodegenerative conditions group and 
significantly decreased from baseline to ±40 cmH2O (p <0.05). Median PCF increased from 
180 to 220L/min in the ALS group and from 170 to 200L/min in the neurodegenerative 
condition group.  
Bach 1993 (14), Chatwin et al (15) Mustfa et al 2003 (16) and Sancho et al 2004 (17) 
compared combinations of MIE, manual assisted cough (MAC) and breath stacking in 
people with ALS and other neurodegenerative conditions, using PCF as an outcome. For 
patients with ALS (n = 73, (16, 17)), MIE was more effective than MAC in those patients 
without bulbar involvement and who are stable. MIE was not effective in those with bulbar 
dysfunction and those with little lung function impairment.  The specific issue of bulbar 
involvement highlights the importance of impaired cough due to upper airway weakness 
which may not be overcome by these interventions (16). In people with other 
neurodegenerative conditions, Bach (14) found MIE more effective than MAC with breath 
stacking; cough with insufflations and unassisted cough. Chatwin et al (15) found that 
although MIE and exsufflation alone were better than unassisted cough, they were not 
significantly better than assisted cough, in a mixed adult and child sample. In a small study 
of 10 patients with neurodegenerative conditions, Trebbia et al (18) found a combination of 
MAC and manual hyperinflation significantly improved PCF. 
An alternative aid to cough may be a mechanical glottis device that imitates glottis closure. 
Suleman et al (19) investigated the mechanical glottis in healthy controls and people with 
bulbar problems and demonstrated that the device created a PEFR significantly higher than 
that of both a straightforward PEFR manoeuvre and a cough manoeuvre, in people with 
bulbar problems.  
Physiotherapy based interventions to improve cough effectiveness by increasing PCF have 
some efficacy for people with neurodegenerative conditions.  Mechanical insufflation-
exsufflation and manually assisted cough appear to be more effective than unassisted 
cough. The choice of intervention depends upon the patient’s vital capacity and whether 
there is bulbar involvement. The heterogeneous populations used including 
neurodegenerative and neuromuscular disorders make it difficult to draw conclusions for 
specific disease populations. 
 
Intervention to mobilise secretions 
The above interventions focused on increasing flows necessary to expectorate secretions, 
whereas high frequency chest wall oscillation (HFCWO) aims to mobilise secretions. In three 
studies with a total of 62 patients with ALS, HFCWO was applied twice a day for 10-30 
minutes per session (20-22). Although there were no significant changes in respiratory 
function (SaO2, FVC, PCF), breathlessness decreased significantly (20) and 92% felt better 
after treatment (22). Based on this, HFCWO may enhance mobilisation of secretions in 
people with neurodegenerative conditions, but large scale studies are necessary to provide 
conclusive findings. 
 
Summary of the problem of retained secretions 
Studies on management of retained secretions have focused on increasing lung volumes to 
create flow rates sufficient to mobilise and expectorate secretions. Evidence suggests that 
improvements in PCF may be gained through maximal insufflation-exsufflation and manually 
assisted cough; further research into their effectiveness in different sub groups of people is 
needed. The use of PCF is a consistent outcome yet would benefit further studies on 
reliability.  
   
The problem of decreased respiratory muscle strength 
Two main therapies were identified to address the problem of respiratory muscle weakness; 
non invasive ventilation (NIV) and respiratory muscle training. NIV aims to reduce the work 
of breathing and conserve energy whilst respiratory muscle training aims to strengthen 
inspiratory and expiratory muscles and improve endurance. Studies of effectiveness of these 
interventions include a systematic review of eight randomised control trials, five randomised 
controlled trials, five prospective observational studies, two retrospective observational 
studies and five experimental studies; see Tables 3 and 4 for details. 
 
Non-invasive ventilation 
Ten studies (see Table 3) involved non invasive ventilation as an intervention. The 
systematic review was specific to ALS. Other studies included 391 people with ALS and 68 
mixed population studies. Studies were mainly prospective observational studies (n= 5), with 
two retrospective studies and two experimental studies. Interventions included Bi level 
positive airway pressure (BiPAP), volume cycled NIV and pressure cycled NIV. Outcome 
measures included FVC, SNIP, MIP, MEP, respiratory muscle endurance and lung 
compliance. 
 
Table 3 
 
A systematic review (23) identified eight randomised control trials investigating the efficacy 
of nocturnal mechanical ventilation in relieving hypoventilation related symptoms in patients 
with neuromuscular and chest wall disorders. Neuromuscular in this review included people 
with ALS. The primary outcome measure was reversal of daytime hypoventilation symptoms 
with few studies reporting lung function measurements. The findings of the review suggest 
benefit of NIV in the short term, but the evidence is weak. 
Seven studies, not included in the above review, investigated the effect of NIV on lung 
function in people with ALS (n= 391). Four studies (n= 282) demonstrated a slower decline 
in FVC in people tolerating NIV (24-27). NIV intervention was individualised to the patient by 
mode and length of time of intervention. The evidence is weakened by the fact that Kleopa et 
al (26) and Carratu et al (25) are retrospective studies.  
Inconclusive evidence exists in relation to other measures of lung function. Aboussouan et al 
(28) found no change in FVC, FEV1, MIP or MEP; Butz et al (29) identified increased 
oxygenation (SaO2 and PaO2) and Lechtzin et al (8) showed increased lung compliance 
following NIV. Two studies including 29 subjects with a range of neurodegenerative 
conditions identified increased respiratory muscle endurance (30) and improved oxygenation 
(31) following NIV intervention. 
 
Summary of findings on non-invasive ventilation 
The key findings are that NIV may influence lung function in people with ALS/MND and it is 
recommended to improve quality of life and survival as well as alleviating breathlessness.  
The role of NIV in the management of other neurodegenerative conditions needs to be 
explored.  
 
Respiratory muscle training 
Respiratory muscle training techniques using the same principles as those for skeletal 
muscle training i.e. overload, specificity and reversibility, have been shown to improve 
respiratory strength and endurance in healthy subjects (32) and in chronic respiratory 
disease (33). Training may also influence respiratory muscle endurance, dependent upon 
the training protocol. Outcome measures include maximal inspiratory pressure (MIP), 
maximal expiratory pressure (MEP) and 12 second maximal voluntary ventilation (12MVV). 
 
Nine studies, including four randomised control studies (see Table 4), assessed the effect of 
respiratory muscle training in people with neurodegenerative conditions.  Two randomised 
control studies in 61 people with multiple sclerosis (34, 35) and one study including 20 
people with Parkinson’s disease (36) identified significant increases in MIP following 
inspiratory muscle training (IMT). The trial by Cheah et al (37) only demonstrated trends of 
increased inspiratory pressure measured by MIP and sniff nasal inspiratory pressure when 
compared to sham IMT in 19 people with ALS. Studies lasted between 10 and 12 weeks with 
training ranging from daily to every other day. Although Fry et al (34) did not see a change in 
maximal voluntary ventilation (MVV), Inzelberg et al (36) did see a significant increase in 
inspiratory muscle endurance as measured by the peak pressure obtained on breathing 
against progressive loads to fatigue.  
 
Table 4 
 
The efficacy of expiratory muscle training is less clear than that of IMT.  Two randomised 
control trials demonstrated significant increases in MEP in 48 people with multiple sclerosis 
compared to breathing exercises (1) and control group (38). Chiara et al (39) also found 
significant increases in MEP in 17 people with multiple sclerosis after 8 weeks training. A 
shorter study by Pitts et al (40) of 4 weeks EMT in people with Parkinson’s disease showed 
a significant increase in MEP, but no difference in peak cough flow. The length of training 
(daily for 3 months (1, 38); daily for 8 weeks (39); 5 days/week for 4 weeks (40)) and 
different stages of disease (mild (38) mild/moderate (39, 40) and severe (1)) may explain the 
different results. 
In a pilot study by Olgiati et al (41), 8 people with multiple sclerosis were assigned either IMT 
or EMT, dependent upon whether the subjects MIP or MEP was < 70% predicted. Although 
training was only for 4 weeks, significant increases were observed in MIP, MEP and MVV for 
the whole group. 
 
Summary of studies on respiratory muscle training 
There is some evidence that respiratory muscle training does increase strength and 
endurance. The majority of studies were carried out on people with multiple sclerosis and 
therefore results may be specific to this population. Although a number of studies were 
randomised controlled trials, interventions and outcomes used differed, limiting firm 
conclusions. Further research is needed to investigate pathophysiological changes occurring 
in respiratory muscles of people with neurodegenerative conditions and the physiological 
and clinical effects of respiratory muscle training.  
 
The influence of exercise on respiratory function 
Six studies investigated the influence of different types of exercise in people with 
neurodegenerative conditions (see Table 6). Three studies (n=168 people with multiple 
sclerosis (42-44)) compared bike training with neurological rehabilitation with only Mostert 
and Kesselring (42) finding a significant difference in FVC and PEFR in the exercise group. 
A specific pulmonary rehabilitation program in 9 people with Parkinson’s disease (45) and 
diaphragmatic training in 8 people with ALS (46) did not show any significant changes in 
respiratory function. In contrast, an intervention of breathing enhanced upper extremity 
exercise in 40 people with multiple sclerosis demonstrated a trend of increased FVC and 
MEP compared to a control group (47). The lack of significant changes in respiratory 
function may be due to the length of the training programmes which ranged from 3 to 8 
weeks. 
Further research is needed in terms of the effects of general exercise in people with 
neurodegenerative conditions and how this is influenced by and influences respiratory 
function. 
 
Discussion 
 
Summary of evidence 
This review selected 35 studies related to physiotherapy based interventions for respiratory 
function. Interventions were summarised as those aiming to: improve cough effectiveness; 
mobilise secretions; decrease the work of breathing; increase strength of the respiratory 
muscles; influence respiratory function through exercise. The evidence selected was weak 
due to both lack of power and reproducibility of interventions, as highlighted in Table 2. 
Synthesis of evidence through a meta-analysis was not possible due to heterogeneous 
populations, interventions and outcome measures; thus a narrative review was undertaken. 
Cough effectiveness may be improved by using maximal insufflation/exsufflation and 
manually assisted cough. High frequency chest wall oscillation to mobilise secretions did not 
influence respiratory function but may reduce breathlessness. The evidence for these 
positive effects is weak. Non-invasive ventilation to reduce the work of breathing may have 
an influence on lung function in the short term. Respiratory muscle strength and endurance 
may be improved using specific training programmes. The evidence relating to exercise as 
an intervention to improve lung function was inconclusive. 
This weak evidence base and anecdotal evidence from discussions with the European 
Huntington’s Disease Network Physiotherapy Working Group (http://www.euro-
hd.net/html/network/groups/physio) indicates that further research is needed in people with 
neurodegenerative conditions. Knowledge gaps exist in a number of specific areas. Firstly, 
the mechanisms underlying respiratory problems in people with neurodegenerative 
conditions such as multiple sclerosis, Parkinson’s disease, Huntington’s disease and motor 
neurone disease are unknown. Respiratory function throughout disease progression needs 
to be explored in order to identify when changes occur and therefore when physiotherapy 
interventions, both preventative and restorative, should be implemented. The effectiveness 
of physiotherapy interventions can be explored through studies with bigger numbers, which 
could be achieved through multi-centre trials, using PCF, MIP and MEP as outcome 
measures. The over arching aim of further research would be to provide evidence based 
guidelines for the management of respiratory problems specific to people with 
neurodegenerative conditions. 
 
Limitations 
The review is limited by the number and quality of studies and consequently a meta–analysis 
was not feasible. Studies had heterogeneous populations, were under powered, often non-
randomised and of insufficient number to provide guidelines for management of the different 
stages of progressive conditions. Interventions and outcome measures were not 
standardised between studies. 
The process of review was limited by having one reviewer rather than two, thus introducing 
potential bias to the review. This was minimised by using the PICO structure (10) for 
searching and the CASP appraisal tool (12).  
 
Conclusions 
The evidence to support the use of methods to increase cough effectiveness, respiratory 
muscle strength and endurance in people with neurodegenerative conditions is weak but 
does indicate a positive effect. The strongest evidence is for the use of non invasive 
ventilation in people with ALS to alleviate symptoms of chronic hypoventilation. Further 
research must be focused towards developing guidelines for effective management of 
respiratory problems in people with neurodegenerative conditions that take into 
consideration the pathophysiological similarities and differences in those conditions. 
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Key to abbreviations: 
 
Conditions 
ALS  Amyotrophic lateral sclerosis 
MND  motor neurone disease 
MS   multiple sclerosis 
NDC  neurodegenerative conditions 
PD  Parkinson’s disease 
Hc  healthy control 
Interventions 
BiPAP  bi level positive airway pressure 
Br exs  breathing exercises 
EMT  Expiratory muscle training 
HFCWO High frequency chest wall oscillation 
IMT  Inspiratory muscle training 
MAC  Manually assisted cough 
MIC  Maximal insufflation capacity 
MIE  mechanical insufflation-exsufflation 
MHI  manual hyperinflation 
NIV  non-invasive ventilation 
RMT  respiratory muscle training 
Outcomes 
12MVV 12 second maximal voluntary ventilation  
ABG  Arterial blood gases 
FEV1  Forced expiratory volume in 1 second 
FER  Forced expiratory ratio 
FVC  Forced vital capacity 
MEP  maximal expiratory pressure 
MIP  maximal inspiratory pressure 
MVV  maximal voluntary ventilation 
PaCO2  Partial pressure of carbon dioxide 
PaO2  Partial pressure of oxygen 
PCF  Peak cough flow 
PEFR  peak expiratory flow rate 
SaO2  % saturation of oxygen 
SNIP  sniff nasal inspiratory pressure 
TLim  respiratory muscle endurance time 
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Tables  
 
 
Table 1 Summary of critical appraisal of all selected studies 
 
 Study 
design 
Focused 
question 
Appropriate 
design 
Population 
defined 
Sample 
size 
calculation 
Allocation 
defined 
Intervention 
reproducible 
Outcome 
measures 
defined 
Data 
analysis 
defined 
Inferential 
analysis 
employed 
Appropriate 
interpretation 
generalisability Clinical 
relevance 
discussed 
Annane  
et al (24) 
EBR yes yes yes n/a n/a n/a yes yes n/a yes yes yes 
Aboussouan 
et al(29) 
Obs 
(P) 
yes yes yes no n/a no yes yes yes yes no yes 
Bach (15) 
 
Exp yes yes yes no n/a no yes no yes yes no yes 
Bourke et al 
(25) 
Obs 
(P) 
yes yes yes no n/a yes yes no yes yes no yes 
Butz et al 
(30) 
Obs 
(P) 
yes yes yes no n/a no yes yes yes yes no yes 
Carratu et al 
(26) 
Obs 
(R) 
yes yes yes no n/a yes yes yes yes yes no yes 
Chaisson 
et al (22) 
Exp yes yes yes no yes no yes yes yes yes no yes 
Chatwin  
et al (16) 
Exp yes yes yes no n/a yes yes yes yes yes no yes 
Cheah et al 
(38) 
RCT yes yes yes no yes yes yes yes yes yes no yes 
Chiara et al 
(40) 
Exp yes yes yes no n/a yes yes yes yes yes no yes 
Fry et al 
(35) 
RCT yes yes yes no yes yes yes yes yes yes no yes 
Gosselink 
et al (1) 
RCT yes yes yes yes yes yes yes yes yes yes yes yes 
Goldstein et 
al (31) 
Exp yes yes yes no n/a no yes yes yes yes no yes 
Inzelberg  
et al (37) 
Exp yes yes yes no yes yes yes yes yes yes no yes 
Jackson  
et al (23) 
Obs 
(R) 
yes no yes no n/a no yes yes yes yes no yes 
Kleopa 
et al (27) 
 
Obs 
(R) 
yes yes yes no n/a no yes yes yes yes no yes 
 Study 
design 
Focused 
question 
Appropriate 
design 
Population 
defined 
Sample 
size 
calculation 
Allocation 
defined 
Intervention 
reproducible 
Outcome 
measures 
defined 
Data 
analysis 
defined 
Inferential 
analysis 
employed 
Appropriate 
interpretation 
generalisability Clinical 
relevance 
discussed 
Klefbeck & 
Hamrah 36) 
RCT yes yes yes no yes yes yes yes yes yes no yes 
Koseoglu  
et al (46) 
Exp yes yes yes no n/a no yes yes yes yes no yes 
Lange 
et al (21) 
RCT yes yes yes no yes yes yes yes yes yes yes yes 
Lechtzin 
et al (8) 
Exp yes yes yes no n/a yes yes yes yes yes no yes 
LoCoco 
et al(28) 
Obs 
(P) 
yes yes yes no n/a yes yes yes yes yes no yes 
Mostert & 
Kesselring 
(43) 
Exp yes yes yes no yes no yes yes yes yes no yes 
Mustfa et al Exp no yes yes no n/a yes yes yes yes yes no yes 
(17) 
Mutluay 
et al (48) 
RCT yes yes yes no yes yes yes yes yes yes yes yes 
Nardin et al 
(47) 
Exp yes yes yes yes n/a yes yes yes yes yes no yes 
Nauffal 
et al (32) 
Obs 
(P) 
yes yes yes no n/a yes yes yes yes yes no yes 
Olgiati 
et al (42) 
Exp yes yes yes no n/a no yes no yes yes no yes 
Pitts et al 
(41) 
Exp yes yes yes no n/a yes yes yes yes yes no yes 
Rampello 
et al (45) 
Exp yes yes yes no yes no yes yes yes yes no yes 
Rasova  
et al (44) 
Exp no yes yes no yes no yes yes yes yes no yes 
Sancho 
et al (18) 
Exp yes yes yes no n/a yes yes yes yes yes no yes 
Smeltzer et 
al (39) 
RCT yes yes yes no yes no yes yes yes yes no yes 
Suleman 
et al (20) 
Exp yes yes yes no n/a yes yes yes yes yes no yes 
Trebbia et al 
(19) 
Exp  yes yes yes no n/a yes yes yes yes yes no yes 
Winck et al 
(14) 
Exp yes yes yes no n/a yes yes yes yes yes no yes 
Key 
EBR   Evidence based review 
Exp   Experimental 
Obs (P) Observational (prospective) study 
Obs (R)  Observational (retrospective) study 
RCT   Randomised controlled trial 
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Table 2  Detail of studies related to retained secretions 
 
Study Population Intervention and method Relevant 
Outcome 
measure 
Key significant 
findings 
Bach 
1993 (15) 
21 NDC MIC, MIC &  MAC, MIE 
Single group; repeated 
measures from 
interventions. MIE = 
several 5 cycle 
applications at 
comfortable pressures 
PCF MIE better than MIC 
&MAC which was better 
than MIC at ↑ PCF 
Chatwin 
et al 
2003 (16) 
21 adult 
and child 
NDC 
Unassisted cough, 
physiotherapy assisted 
cough, non-invasive 
ventilator assisted cough, 
exsufflation assisted 
cough, 
insufflations/exsufflation 
assisted cough 
Single group; repeated 
measures from each 
intervention. 
PCF Exsufflation assisted 
cough and 
insufflation/exsufflation 
cough better than 
unassisted cough 
Chaisson 
et al 
2006 (22) 
9 ALS HFCWO, standard 
treatment 
2 groups: group 1 - 
standard care plus 
FVC No difference in rate of 
decline in FVC between 
HFCWO and standard 
treatment 
27 
  
HFCWO applied for 
15min, twice daily; group 
2 - standard care. Both 
groups received 
instruction on cough 
augmentation 
manoeuvres 
Jackson 
et al 
2006 (23) 
18 ALS HFCWO 
Retrospective study, 
HFCWO applied twice 
daily for 10-20 minutes or 
more frequently if needed. 
Frequency = 10-14 Hz, 
pressures 30 – 40 cmH2O     
PCF No significant changes 
Lange et 
al 2006 
(21) 
46 ALS HFCWO, no treatment 
RCT. HFCWO – twice 
daily for 10-15 minutes, 
for 12 weeks. Frequency = 
10-12 Hz, pressures 1-4 
(linear scale no units). 
Control group – no 
treatment.  
PEFR, 
dyspnoea, 
FVC 
 
↓dyspnoea; FVC 
decreased in control 
group and not the 
HFCWO group. 
Mustfa et 
al 2003 
(17) 
47 ALS Cough, MAC, maximal 
exsufflation, maximal 
insufflation,  MIE 
Single group, repeated 
measures from each 
PCF Exsufflation and MIE ↑ 
PCF 
28 
  
intervention. 
Sancho 
et al 
2004 (18) 
26 ALS MAC, MIE & MAC 
Single group, repeated 
measures from each 
intervention. MIE = 
pressure 40 to -40 
cmH2O, I/E ratio 2:3 with 1 
sec pause. 
PCF MIE can increase PCF 
in stable patients with 
ALS with  4L/s < PCFMIC 
> 2.7L/s 
Suleman 
et al 
2004 (20) 
10 MND Mechanical glottis, cough 
Single group, repeated 
measures from each 
intervention 
PEFR ↑ PEFR with 
mechanical glottis. 
PEFR with mechanical 
glottis > PEFR with 
cough 
Trebbia 
et al 
2005 (19) 
10 NDC MHI, MAC, MI & MAC 
Single group, repeated 
measures from each 
intervention. 
PCF PCF higher  during MI & 
MAC than MI and MAC 
alone 
Winck et 
al 2004 
(14) 
13 ALS 
7 NDC 
MIE 
Single group, measures 
taken before and after 
MIE. MIE = 6 I-E cycles at 
each of 15 to -15 cm H2O, 
30 to -30 cm H2O, 40 to -
40 cm H2O;  I/E ratio 3:4 
with 4 sec pause between 
each cycle. 
PCF, 
SaO2, 
dyspnoea 
↑ PCF, SaO2 
↓dyspnoea 
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Table 3 Detail of studies related to NIV intervention for decreased respiratory muscle 
strength 
Study Population Intervention and 
method 
Relevant 
Outcome 
measure 
Key significant 
findings 
Annane et 
al 2009 (24) 
Neuromuscular 
or chest wall 
disorders 
Nocturnal mechanical 
ventilation 
Cochrane review 
FVC, SNIP, 
SaO2 
Current evidence 
weak but 
consistent that 
nocturnal 
mechanical 
ventilation 
alleviates chronic 
hypoventilation in 
the short term. 
Aboussouan 
et al 2001 
(29) 
60 ALS NIV 
Single group, repeated 
measures over time. 
NIV = volume 
controlled or BiPAP; 
pressures – for patient 
comfort; for as long as 
tolerated during night 
and as necessary 
daytime. 
 
 
FVC, FEV1, 
MIP, MEP 
No significant 
change in 
outcomes over time  
Bourke et al 17 ALS BiPAP FVC Rate of decline in 
30 
  
2003 (25) Single group, repeated 
measures over time. 
BiPAP = pressures – 
dependant on arterial 
blood gases, oxygen 
saturation and 
compliance; timing 
adjusted for patient 
comfort. 
FVC slower post 
treatment 
Butz et al 
2003 (30) 
30 ALS NIV 
Single group, repeated 
measures over time. 
NIV = pressure cycled; 
pressures 8-22 
millibars dependent 
upon arterial blood 
gases, oxygen 
saturation and relief of 
symptoms 
FVC, SaO2, 
PaO2, 
PaCO2 
SaO2 and PaO2 
increased over time 
Carratu et al 
2009 (26) 
72 ALS NIV 
Retrospective 
comparing 3 groups 
according to FVC and 
NIV use. NIV = volume 
controlled or BiPAP; 
pressures – 8 cmH2O 
IPAP, 3 cmH2O EPAP; 
FVC, FEV1,  
PaO2, 
PaCO2 
FVC decline slower 
in survivors who 
tolerated NIPPV 
31 
  
volume/pressure 
dependent upon chest 
rise, leaks and 
comfort; used nightly 
as tolerated and as 
necessary daytime. 
Goldstein et 
al 1991 (31) 
6 inc 2 NDC NIV 
Single group, repeated 
measures over time. 
NIPPV = volume 
cycled 
Tlim Tlim ↑ at 3 months 
post intervention  
Kleopa et al 
1999 (27) 
122 ALS BiPAP 
Retrospective 
comparing 3 groups – 
those who tolerated 
BiPAP for > 4 hours, 
those that tolerated < 
4 hours and those who 
refused. 
%FVC 
predicted 
Decline of %FVC 
slower in those 
who could tolerate 
NIPPV 
Lechtzin et 
al 2006 (8) 
19 ALS, 4 Hc BiPAP 
2 groups, measured 
before and after 
BiPAP. BiPAP = 5 
minutes; pressure 
dependent upon lung 
compliance 
 
FEV1, FVC, 
FER, MIP, 
MEP, static 
lung 
compliance 
Lung compliance 
↑with BiPaP in ALS 
group, no change 
in control group 
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LoCoco et 
al 2006 (28) 
71 ALS BiPAP 
Single group, repeated 
measures over time. 
BiPAP = pressures 
adjusted to patient 
comfort, leaks and 
efficiency of 
ventilation; for as long 
as tolerated nightly 
and as necessary 
daytime 
FVC Decline of FVC 
slower in those 
who could tolerate 
NIPPV 
Nauffal et al 
2002 (32) 
62 inc 27 NDC BiPAP 
Single group, repeated 
measures over time. 
BiPAP nightly; 
pressures dependent 
on arterial blood 
gases. 
FEV1, FVC, 
FER, MIP, 
MEP, ABG 
SaO2, ↑ after 3 
months 
FEV1, FVC ↓ after 
12 months 
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Table 4 Detail of studies related to respiratory muscle training intervention for 
decreased respiratory muscle strength 
Study Population Intervention Relevant 
Outcome 
measure 
Key significant 
findings 
Cheah et 
al 2009 
(38) 
19 ALS IMT group vs. Sham 
group 
IMT 10 minutes, 3 times 
daily, 12 weeks. 
Resistance increased 
weekly from 15 to 60% 
SNIP, then sustained at 
60% SNIP. 
Sham device had no 
resistance. 
FVC, MIP, 
SNIP, MEP 
FVC, MIP, SNIP ↑ 
trend 
Chiara et 
al 2006 
(40) 
17 MS, 14 
Hc 
EMT 
Repeated measures pre 
EMT , post EMT and 4 
weeks after no training.  
EMT 4 sets of 6 
repetitions, 5 days a 
week, 8 weeks. 
Resistance increased 
weekly from 40 to 80% 
MEP then sustained at 
80% MEP 
FVC, FEV1,  
MEP, PEFR 
MEP, PEF ↑after 8 
weeks training. No 
difference between 
MS and hc 
Fry et al 46 MS Home IMT group vs. MIP, MEP, MIP ↑ 
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2007 (35) Control group 
IMT 3 sets of 15 
repetitions, daily for 10 
weeks. Resistance 
increased from 30% MIP 
according to Borg RPE 
and symptoms. 
Control: no intervention. 
MVV 
Gosselink 
et al 2000 
(1) 
28 MS EMT group vs. br exs 
group 
EMT 3 sets of 15 
repetitions, twice daily for 
3 months. Resistance 
was 60% MEP. 
Br exs to enhance 
maximal inspirations 
 
FVC, MIP, 
MEP 
MIP ↑after 3 months 
training, no 
difference between 
EMT and br exs. 
MEP ↑after 3 
months and 
significant 
compared to br exs 
Inzelberg 
et al 2005 
(37) 
20 PD IMT group vs. Control 
group 
IMT 30mins, 6 
days/week, 12 weeks. 
Resistance increased 
from 15 to 60% MIP and 
sustained at 60% MIP. 
Control frequency as 
IMT. Resistance 7 
cmH2O 
FVC, MIP, 
Peak max 
endurance 
MIP and endurance 
↑; no change in 
FVC; no change in 
control group. 
35 
  
Klefbeck 
and 
Hamrah 
2003 (36) 
15 MS IMT group vs. Control 
group 
IMT 3 sets of 10 
repetitions, twice every 
other day, 10 weeks.  
Resistance 40-60% MIP, 
dependent upon Borg 
RPE < 17 
Control deep breathing 
exercises as part of 
physiotherapy treatment. 
FVC, FEV1,  
MIP, MEP, 
PEFR 
MIP and MEP ↑ 
from baseline.  
MIP significantly ↑ 
compared to control. 
Olgiati et 
al 1988 
(42) 
8 MS IMT /EMT dependent 
upon % MIP/MEP 
Training 6-10 minutes, 
twice/day, 5 days/ week 
for 4 ±1 week. 
Resistance dependent 
upon %MIP/MEP and 
progressively increased. 
MIP, MEP, 
MVV 
 
MIP, MEP, MVV ↑ 
Pitts et al 
2009 (41) 
10 PD EMT 
Repeated measures over 
time 
Training 5 sets of 5 
breaths, once/day, 5 
days week for 4 weeks. 
Resistance 75% of MEP 
MEP, PCF MEP ↑ 
Smeltzer 20 MS EMT group vs. Control MIP, MEP MEP↑ 
36 
  
et al 1996 
(39) 
group 
EMT 3 sets of 15 
repetitions, twice daily for 
3 months. 
Resistance based on 
MEP and increased 
based on ability to 
perform exercises. 
Control frequency as 
EMT, with IMT at 
resistances too low to 
affect inspiratory muscle 
strength. 
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Table 5 Detail on studies based on exercise and its influence on respiratory function  
Study Population Intervention Relevant 
Outcome 
measure 
Key significant 
findings 
Koseoglu 
et al 1997 
(46) 
9 PD Pulmonary rehabilitation 
Single group compared 
before and after 
intervention. 
Pulmonary Rehabilitation 
60 minutes, 3 days/week 
for 5 weeks. 
FVC, FEV1, 
PEFR, MVV 
No significant 
changes 
Mostert 
and 
Kasserling 
2002 (43) 
37 MS, 26 
Hc 
MS exercise training 
(bike)group vs. MS control 
group vs Hc group vs 
healthy exercise training 
group 
Training 30 minutes, 5 
times/week for 3-4 weeks, 
individualised intensity. 
MS Control group – 
normal physiotherapy 
Hc group – no physical 
exercise that could 
improve aerobic fitness 
FVC, FEV1, 
FER, PEFR, 
MVV, aerobic 
capacity 
FVC, PEFR ↑ in 
exercise group; no 
change in aerobic 
capacity 
Mutluay et 
al 2007 
(48) 
62 MS Breathing enhanced upper 
extremity exercises group 
vs. Control group 
FVC, FEV1, 
FER, MIP, 
MEP 
FEV1, FER ↑ in 
compared to 
control. 
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Breathing exercises 
programme 30 minutes, 
once/day for 6 weeks 
MEP ↑trend 
compared to 
control 
Nardin et 
al 2008 
(47) 
8 ALS Diaphragmatic training 
Single group measured 
before and after 
intervention. 
Training 5 sets of 10 
minutes daily for 12 weeks 
FVC, 
hypercapnic 
ventilatory 
response 
No change  
Rampello 
et al 2007 
(45) 
19 MS Aerobic training (cycle 
ergometer) vs. 
neurological rehabilitation 
Randomised cross over 
study. 
Training 55 minutes, 3 
times/week for 8 weeks. 
Intensity dependent on 
work rate and increased to 
80% maximum work rate 
Rehabilitation 60 minutes, 
3 times/week for 8 weeks.  
 
FVC, FEV1, 
MIP, MEP 
No difference in 
lung function  
Rasova et 
al 2006 
(44) 
112 MS Neurophysiological 
physiotherapy vs. aerobic 
bike training vs. mixed vs. 
Control 
Physiotherapy 1 hour, 
FVC, FEV1, 
PEFR 
PEFR ↑ in 
intervention 
groups, no 
difference 
between groups 
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twice/week for 2 months 
Bike training twice/week, 
intensity 60% maximal 
oxygen uptake, time 
dependent on disability 
score range 10-30 minutes 
Mixed training 1 hour 
twice/week physiotherapy 
and bike training as 
above. 
Control – no intervention. 
 
 
